Zanubrutinib Shows Superior Efficacy and Persistence Over Other BTK Inhibitors in CLL and B-Cell Lymphomas
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.